ANN ARBOR, Mich., Sept. 27 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of serious infections, today announced that Robert C. Moellering, Jr., M.D., has been named to its Board of Directors.
“Dr. Moellering brings over 30 years of extensive medical experience to the NanoBio Board,” stated James R. Baker, Jr., M.D., Chairman of the Board. “He is broadly recognized as a worldwide expert in the areas of infectious diseases and antimicrobial technologies. His experience and guidance will be instrumental to us, as we evaluate additional treatment areas to pursue based on our platform technology, and new product candidates that we might acquire or in-license in the future.”
Dr. Moellering is the Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School. From 1998 to 2005, he served as the Herrman Ludwig Blumgart Professor of Medicine at Harvard Medical School and Physician-in-Chief and Chairman of the Department of Medicine at the Beth Israel Deaconess Medical Center. Dr. Moellering received his M.D. degree cum laude from Harvard Medical School and continued his distinguished career at Massachusetts General Hospital and Harvard Medical School. He has also served as President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center. Dr. Moellering has been actively involved in research on the mechanisms of action and mechanisms of resistance of antimicrobial agents for the past 25 years. He has defined some of the important mechanisms of interaction of antimicrobial agents, which have been reported extensively in scientific journals. He is the Editor-in-Chief Emeritus of Antimicrobial Agents and Chemotherapy, Editor of Infectious Disease Clinics of North America, and Editor of the European Journal of Clinical Microbiology and Infectious Diseases.
About NanoBio Corporation
NanoBio(R) Corporation is a privately-held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), methicillin resistant Staphylococcus aureus (MRSA), and a mucosal vaccine for influenza. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.
NanoBio Contact: John Coffey Vice President, Business Development john.coffey@nanobio.com (734) 302-4000 x107
NanoBio Corporation
CONTACT: John Coffey, Vice President, Business Development of NanoBioCorporation, +1-734-302-4000 x107, john.coffey@nanobio.com
